In contrast, reprogrammed T cells expressing a gain-of-function EZH2 mutant displayed an enhanced ability to inhibit tumor growth in vitro and in vivo, thus suggesting that manipulation of T-cell EZH2 in cellular therapies may provide cellular products able to withstand solid tumor metabolically deficient environments [177,178]. The gene discussed is EZH2; the disease is neoplasm.